Sichuan Kelun-Biotech Biopharmaceutical revenue and financials
$468.60Change from previous close: −1.97%Absolute change: −$9.40
In the fiscal year ended December 2025, Sichuan Kelun-Biotech Biopharmaceutical reported revenue of ¥2.06B (+6.46% year over year). The net loss was ¥381.97M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +6.46%
- 2025 vs 2024
- Net margin
- -18.6%
- 2024: -13.8%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|
| Total assets | 6,322 | 5,989 | 5,953 |
| Current assets | 5,512 | 5,149 | 5,193 |
| Cash and equivalents | 2,770 | 3,331 | 3,116 |
| Short-term investments | 2,002 | 1,228 | 1,411 |
| Inventory | 272 | 241 | 200 |
| Net property, plant and equipment | 738 | 723 | 741 |
| Other intangible assets | 0.2 | 37.1 | — |
| Current liabilities | 870 | 1,004 | 790 |
| Accounts payable | 443 | 409 | 337 |
| Total debt | 81.4 | 88.4 | 131 |
| Total liabilities | 985 | 1,121 | 939 |
| Total equity (incl. minority) | 5,337 | 4,867 | 5,014 |
| Retained earnings | -4,317 | -4,705 | -4,468 |